BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Short (1M)
Nomura Recommends 'Buy' On Lupin
According to Nomura, due to delays in approvals, the sales potential of the pending abbreviated new drug applications (ANDAs) from the Goa and
Indore Unit 2 sites have reduced significantly. However, given the concerns surrounding the Indore unit, lower sales from new launches have been factored into the earnings model, the brokerage adds.